1. Foghorn hits NASDAQ in $120M debut as biotech IPO keeps rolling — Bayer drug shown to slow diabetic kidney disease — Another opioid exec heads to prison — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Quest Diagnostics and BioReference

Discussion in 'Quest Diagnostics' started by anonymous, Nov 15, 2019 at 9:23 AM.

  1. anonymous

    anonymous Guest

    Already in the works for certain and some say it’s a done deal. What are the implications?
     
  2. anonymous

    anonymous Guest

    Just an FYI to the folks at Bio. When Cindy tells you that Quest is definitely not buying you. Then we’re definitely buying you. Hope this helps.
     
  3. anonymous

    anonymous Guest

    Among the implications are that many Quest rejects and those that rejected Quest will be on the street.
     
  4. anonymous

    anonymous Guest

    So untrue. Quest will keep their rejects.
     
  5. anonymous

    anonymous Guest

    All are welcome
     
  6. anonymous

    anonymous Guest

    Many considered, few chosen.
     
  7. anonymous

    anonymous Guest

    Cindy can write her own ticket. She’s a hot commodity in high demand. Quest won’t make the mistake of letting her leave again.
     
  8. anonymous

    anonymous Guest

    You Questees are so pathetic. Buying us will never happen. Keep whining about our shady deals and I will keep counting my money.
     
  9. anonymous

    anonymous Guest

    Delusional. We will own BioReference before Christmas and guys like this won’t even get to try out for Team Quest.